Company intelligence / Profile preview

Olink

Uppsala, Sweden

Ownership: Private
Employees: ~350
Development stage: Other

Overview

Olink’s proteomics platform enables high-throughput, highly multiplexed, and sensitive protein quantification, supporting population-scale studies and biomarker discovery for more than 5,400 proteins. The technology underpins advances in disease understanding and drug development, but Olink itself does not pursue its own clinical pipeline.

Therapeutic areas: Other
Modalities: Protein biomarker panelsImmunoassayProteomics analytical platform
Industry: Protein Biomarker Diagnostics

Partnerships

AffymetrixLife TechnologiesSigma-AldrichUK Biobank Pharma Proteomics Projectleading pharma and academic institutions

Beyond the preview

Go deeper on Olink.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Olink.

Explore the full profile